167 related articles for article (PubMed ID: 28614389)
1. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
[TBL] [Abstract][Full Text] [Related]
5. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
[TBL] [Abstract][Full Text] [Related]
6. Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
Ogawa K; Hige S; Nakanishi M; Yamamoto Y; Chuma M; Nagasaka A; Asaka M
Antivir Ther; 2009; 14(4):513-22. PubMed ID: 19578236
[TBL] [Abstract][Full Text] [Related]
7. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
10. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
11. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
12. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
Nishida N; Iwanishi M; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Ida H; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kitano M; Kudo M
Dig Dis; 2015 Oct; 33(6):708-14. PubMed ID: 26488400
[TBL] [Abstract][Full Text] [Related]
13. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
14. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
15. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
16. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
[TBL] [Abstract][Full Text] [Related]
18. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
19. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]